Latest / Research To Practice | Oncology Videos
Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
Featuring an interview with Prof Peter Schmid, including the following topics:
Response to immunotherapy in breast cancer subtypes (0:00)
Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03)
ADC structure and treatment-related adverse events (19:02)
Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06)
Novel ADCs…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.